An Accord for a Healthier World

Progress Update: January 2024

We believe that where you live shouldn't impact the quality of your healthcare, and your income shouldn't determine your health outcomes. An Accord for a Healthier World aims to close the health equity gap and help provide greater access to healthcare innovation for 1.2 billion people living in 45 lower-income countries around the world.

Improving Access to Medicines and Vaccines

Through the Accord, Pfizer has committed to enable access to the full portfolio of medicines and vaccines for which it holds global rights – both current and future products – on a not-for-profit basis to these countries. This includes hundreds of essential medicines and vaccines, as well as breakthrough prevention and treatment options for many of the most significant infectious and non-communicable diseases impacting lower-income countries.



Pfizer is in discussion with **more than half** of the 45 countries regarding access to its portfolio of medicines and vaccines offered through the Accord.



In Rwanda, Pfizer has <u>supplied</u> **+1,500 courses** of innovative medicines and vaccines, which are now available to patients in three national hospitals for the treatment of certain cancers and infectious and inflammatory diseases.



Rwanda, Malawi, Senegal, Ghana, Benin, the Democratic Republic of the Congo and Gambia have signed framework agreements with the intent of accessing Pfizer medicines and vaccines.



Pfizer is actively working with the **seven countries** with agreements in place to enable a seamless supply of selected products in early 2024, including cancer treatments, anti-infectives, vaccines and other therapies.

Accelerating Access and Building Stronger Health Systems



Strengthening Supply Chain Logistics

In collaboration with country governments, the Accord aims to identify solutions that help advance capabilities in end-to-end supply chain management, such as product traceability, cold chain logistics, last-mile delivery and more.

- A Pfizer team of supply chain experts worked with the Rwanda Ministry of Health to implement a <u>track and trace</u> <u>platform</u> to help **monitor the quality and safety** of Pfizer products procured and limit risk of counterfeiting.
- Additional best practice modules are being developed for potential roll out to other Accord-eligible countries.



Accelerating Access and Building Stronger Health Systems (cont.)



Advancing Medical Education and Professional Development

The Accord is collaborating with health authorities and medical associations to provide in-person and virtual medical trainings, online resources and e-learning opportunities on appropriate use of Pfizer medicines and vaccines and broader disease education.

Rwanda Ministry of Health:

- Conducted medical training sessions for **+200 healthcare professionals** in areas including breast cancer, COVID-19 and dermatology.
- Launched a medical information website accessible to **+2,400 healthcare professionals** to provide information about Pfizer's innovative products available across therapeutic areas.

Ghana Ministry of Health:

 Working alongside local healthcare facilities and medical associations for ongoing healthcare professional trainings in antimicrobial stewardship, resistance and susceptibility testing as well as breast cancer and sickle cell disease.

Governments in multiple French-speaking countries in sub-Saharan Africa:

Provided virtual medical education training on rheumatoid arthritis to +220 rheumatologists.



Pursuing More Efficient and Accelerated Regulatory Pathways

The Accord is working with governments to explore opportunities for greater efficiency and harmonization of regulatory pathways that can expedite review timelines, as permissible under local regulations.

• With the African Union Development Agency (AUDA-NEPAD), Pfizer hosted a regulatory roundtable in December 2023 on the sidelines of the 6th Scientific Conference on Medical Products Regulation in Africa (SCoMRA). The session brought together heads of regulatory agencies from seven African countries to align on needs and opportunities to help advance regulatory capabilities and establish a strong and efficient Pan-African regulatory framework.

Supporting Capacity Building Every Step of the Patient Journey

In key areas of Pfizer therapeutic expertise, the Accord is also collaborating with some Accord-eligible governments and other global health experts to identify opportunities to further improve health system capacity and access to quality care.

- The Pfizer Foundation* and the Accord, in collaboration with the Ministries of Health in Rwanda and Malawi, and other global health leaders are supporting implementation of a breast cancer program to provide routine diagnostic and referral solutions that can enable **earlier breast cancer diagnosis**.
- The Malawi Ministry of Health, bioMérieux and Pfizer have signed a Memorandum of Collaboration to reinforce the country's efforts to address **antimicrobial resistance** (AMR) at the hospital level. The multi-sectoral collaboration intends to examine infection prevention and control, diagnosis, treatment and surveillance, aligning AMR resources and expertise to further the Ministry of Health's efforts to build public sector health system capacity and reduce AMR.
- In Rwanda, Pfizer and Becton, Dickinson and Company are collaborating to support local activities at public-sector hospitals in implementing high-impact **antimicrobial surveillance interventions** that aim to **reduce AMR and build institutional capacity**.



^{*}The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.